Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received
“We continue to serve our community during the pandemic with this important testing and have received nearly 55,000 COVID-19 samples since the beginning of 2021,” said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our expectation that COVID-19 RT-PCR testing will be a significant component of our business until the pandemic subsides and the ability of Biocept’s liquid biopsy technology to provide physicians with clinically actionable information, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that our products and services may not perform as expected. These and other risks are described in greater detail under the "Risk Factors" heading of our Quarterly Report on Form 10-Q for the quarter ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005246/en/
Investors:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
Media:
asampson@sampsonprgroup.com
562-304-0301
Source: